Cytokines Secreted by Lymphokine-Activated Killer Cells Induce Endogenous Nitric Oxide Synthesis and Apoptosis in DLD-1 Colon Cancer Cells

Phillips, 1987, In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy, J. Clin. Oncol., 5, 1933, 10.1200/JCO.1987.5.12.1933

Itoh, 1986, Lysis of human solid tumor cells by lymphokine-activated natural killer cells, J. Immunol., 136, 3910, 10.4049/jimmunol.136.10.3910

Grimm, 1985, The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL, Transplantation, 39, 537, 10.1097/00007890-198505000-00016

Grimm, 1985, Cell. Immunol., 94, 568, 10.1016/0008-8749(85)90280-1

Berberg, 1966, Phytohemagglutinin: Inhibition of the agglutinating activity by N-acetyl-d-galactosamine, Science, 154, 1019, 10.1126/science.154.3752.1019

Restifo, 1995, Biology of cellular immune responses

Atkinson, 1998, Cytotoxic T lymphocyte-assisted suicide. Caspase 3 activation is primarily the result of the direct action of granzyme B, J. Biol. Chem., 273, 21261, 10.1074/jbc.273.33.21261

Rouvier, 1993, Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity, J. Exp. Med., 177, 195, 10.1084/jem.177.1.195

Mulé, 1985, The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo, J. Immunol., 135, 646, 10.4049/jimmunol.135.1.646

Lafreniere, 1985, Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma, J. Immunol., 135, 4273, 10.4049/jimmunol.135.6.4273

Eberlein, 1982, Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin-2, J. Exp. Med., 156, 385

Mulé, 1986, The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells, J. Immunol., 136, 3899, 10.4049/jimmunol.136.10.3899

Rosenberg, 1985, Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2, J. Exp. Med., 161, 1169, 10.1084/jem.161.5.1169

Keilholz, 1998, Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients, J. Clin. Oncol., 16, 2921, 10.1200/JCO.1998.16.9.2921

Rosenberg, 1994, Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2, J. Am. Med. Assoc., 271, 907, 10.1001/jama.1994.03510360033032

Herberman, 1986, Annu. Rev. Immunol., 4, 651, 10.1146/annurev.iy.04.040186.003251

Ghosh, 1989, Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2, Int. J. Cancer, 43, 410, 10.1002/ijc.2910430311

McCabe, 1991, The modified Group C experience—Phase III randomized trials of IL-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma, ASCO Proc., 10, 213

Christiansen, 1989, Continuous infusion of recombinant interleukin-2 and lymphokine-activated killer cells in refractory malignancies, Med. Pediatr. Oncol., 17, 455, 10.1002/mpo.2950170521

Lotze, 1980, The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors, J. Immunol., 125, 1487, 10.4049/jimmunol.125.4.1487

Jablons, 1989, IL-6/IFN-β-2 as a circulating hormone: Induction by cytokine administration in humans, J. Immunol., 142, 1542, 10.4049/jimmunol.142.5.1542

Blay, 1991, IL-1 and TNF concentrations as predictive factors of clinical response to IL-2 in patients with renal cell carcinoma, FASEB J., 5, A1772

Hibbs, 1990, Synthesis of nitric oxide from a terminal guanidino nitrogen atom of l-arginine: A molecular mechanism for regulating cellular proliferation that targets intracellular iron

Drapier, 1986, Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involves the iron–sulfur prosthetic group and is reversible, J. Clin. Invest., 78, 790, 10.1172/JCI112642

Granger, 1982, Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells, J. Cell Biol., 95, 527, 10.1083/jcb.95.2.527

Drapier, 1988, Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in l-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells, J. Immunol., 140, 2829, 10.4049/jimmunol.140.8.2829

Kwon, 1991, J. Exp. Med., 174, 761, 10.1084/jem.174.4.761

Amber, 1988, Cytokines induce an l-arginine-dependent effector system in nonmacrophage cells, J. Leukocyte Biol., 44, 58, 10.1002/jlb.44.1.58

Lowenstein, 1994, Nitric oxide: A physiologic messenger, Ann. Intern. Med., 120, 227, 10.7326/0003-4819-120-3-199402010-00009

Yim, 1995, Nitric oxide synthesis in murine skin cancers, J. Korean Cancer Assoc., 27, 101

Phillips, 1986, Dissection of the lymphokine-activated killer cell phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis, J. Exp. Med., 164, 814, 10.1084/jem.164.3.814

Messmer, 1996, Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways, Biochem. J., 319, 299, 10.1042/bj3190299

Hibbs, 1987, l-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells, J. Immunol., 138, 550, 10.4049/jimmunol.138.2.550

Hibbs, 1988, Nitric oxide: A cytotoxic activated macrophage effector molecule, Biochem. Biophys. Res. Commun., 157, 87, 10.1016/S0006-291X(88)80015-9

Stuehr, 1989, Nitric oxide: A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells, J. Exp. Med., 169, 1543, 10.1084/jem.169.5.1543

Lancaster, 1990, EPR demonstration of iron–nitrosyl complex formation by cytotoxic activated macrophages, Proc. Natl. Acad. Sci. USA, 87, 1223, 10.1073/pnas.87.3.1223

Gow, 1996, Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation, FEBS Lett., 385, 63, 10.1016/0014-5793(96)00347-X

Stamler, 1994, Redox signaling: Nitrosylation and related target interactions of nitric oxide, Cell, 78, 931, 10.1016/0092-8674(94)90269-0

Brüne, 1989, Activation of a cytosolic ADP-ribosyltransferase by nitric oxide-generating agents, J. Biol. Chem., 264, 8455, 10.1016/S0021-9258(18)81808-7

Nguyen, 1992, DNA damage and mutation in human cells exposed to nitric oxide in vitro, Proc. Natl. Acad. Sci. USA, 89, 3030, 10.1073/pnas.89.7.3030

Albina, 1993, Nitric oxide-mediated apoptosis in murine peritoneal macrophages, J. Immunol., 150, 5080, 10.4049/jimmunol.150.11.5080

Wink, 1996, Chemical biology of nitric oxide: Regulation and protective and toxic mechanisms, Curr. Top. Cell. Regul., 34, 159, 10.1016/S0070-2137(96)80006-9

Hibbs, 1992, Evidence for cytokine inducible nitric oxide synthesis from l-arginine in patients receiving interleukin-2 therapy, J. Clin. Invest., 89, 867, 10.1172/JCI115666

Sherman, 1993, Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor line, Biochemistry, 32, 11600, 10.1021/bi00094a017

Werner-Felmayer, 1993, Ca2+/calmodulin-dependent nitric oxide synthase activity in the human cervix carcinoma cell line ME-180, Biochem. J., 289, 357, 10.1042/bj2890357

Thomsen, 1995, Nitric oxide synthase activity in human breast cancer, Br. J. Cancer, 72, 41, 10.1038/bjc.1995.274

Arias-Diaz, 1994, Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients, Cancer, 74, 1546, 10.1002/1097-0142(19940901)74:5<1546::AID-CNCR2820740509>3.0.CO;2-F

Gross, 1991, Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages, Biochem. Biophys. Res. Commun., 178, 823, 10.1016/0006-291X(91)90965-A

Hibbs, 1987, Macrophage cytotoxicity: Role for l-arginine deiminase and imino nitrogen oxidation to nitrite, Science, 235, 473, 10.1126/science.2432665

Samlowski, 1996, Tumor cell apoptosis may represent a novel cytotoxic mechanism resulting from IL-2 induced nitric oxide (NO) synthesis

Tai, 1997, Expression of an inducible type of nitric oxide (NO) synthase in the thymus and involvement of NO in deletion of TCR-stimulated double-positive thymocytes, J. Immunol., 158, 4696, 10.4049/jimmunol.158.10.4696

Mannick, 1999, Fas-induced caspase denitrosylation, Science, 284, 651, 10.1126/science.284.5414.651